SCHEMBL2403960

SCHEMBL2403960

O=C1/C(=C/c2ccc(O)c(O)c2)SC(=S)N1c1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPD1 P10809 1/20 0.81
HSPE1 P61604 1/20 0.81
DUSP26 Q9BV47 1/20 0.77
MEN1 O00255 6/20 0.65
KMT2A Q03164 6/20 0.65
GAA P10253 3/20 0.65
POLB P06746 3/20 0.65
NSD2 O96028 2/20 0.65
ALDH1A1 P00352 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
HSP90AA1 P07900 1/20 0.65
CASP3 P42574 1/20 0.65
SENP8 Q96LD8 1/20 0.65
SENP7 Q9BQF6 1/20 0.65
SENP6 Q9GZR1 1/20 0.65
KDM4E B2RXH2 1/20 0.65
JAK2 O60674 1/20 0.65
MAPT P10636 1/20 0.65
MAPK1 P28482 1/20 0.65
HTT P42858 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2403957 1.00 HSPD1 (0.81) HSPD1HSPE1DUSP26MEN1KMT2A
SCHEMBL2403963 1.00 HSPD1 (0.81) HSPD1HSPE1DUSP26MEN1KMT2A
SCHEMBL5455211 0.90 HSPD1 (0.85) HSPD1HSPE1DUSP26MEN1KMT2A
SCHEMBL5455212 0.90 HSPD1 (0.85) HSPD1HSPE1DUSP26MEN1KMT2A
SCHEMBL14788063 0.89 HSPD1 (0.76) HSPD1HSPE1DUSP26MEN1KMT2A
SCHEMBL2489942 0.87 DUSP26 (0.73) HSPD1HSPE1DUSP26MEN1KMT2A
SCHEMBL14788077 0.87 DUSP26 (0.73) HSPD1HSPE1DUSP26MEN1KMT2A
SCHEMBL12637130 0.87 DUSP26 (0.73) HSPD1HSPE1DUSP26MEN1KMT2A
SCHEMBL2489941 0.87 DUSP26 (0.73) HSPD1HSPE1DUSP26MEN1KMT2A
SCHEMBL10035969 0.85 MEN1 (0.73) HSPD1HSPE1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2891649-B1 Prolylhydroxylase inhibitors and methods of use UNIV CORNELL (US) 2018-04-11 EP disclosed
US-9505741-B2 Prolylhydroxylase inhibitors and methods of use CORNELL UNIVERSITY (US) 2016-11-29 US disclosed
EP-2891649-A1 Prolylhydroxylase inhibitors and methods of use Cornell University (US) 2015-07-08 EP disclosed
US-20130023528-A1 PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE CORNELL UNIVERSITY (US) 2013-01-24 US disclosed
EP-2536709-A2 PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE Cornell University (US) 2012-12-26 EP disclosed
WO-2011106226-A2 PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE CORNELL UNIVERSITY (US) 2011-09-01 WO disclosed
US-20080051445-A1 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways NATIONAL INSTITUTE OF IMMUNOLOGY. 2008-02-28 US disclosed
US-20080051445-A1 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways NATIONAL INSTITUTE OF IMMUNOLOGY. 2008-02-28 US disclosed
US-20080051445-A1 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways NATIONAL INSTITUTE OF IMMUNOLOGY. 2008-02-28 US disclosed
EP-1834642-A2 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways National Institute of Immunology (IN) 2007-09-19 EP disclosed
EP-1834642-A2 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways National Institute of Immunology (IN) 2007-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051445-A1 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways FASN, FADS2, TECR HSPD1 1305/4885HSPE1 1885/4885DUSP26 495/4885
US-20130023528-A1 PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE EGLN3, HIF1AN, EGLN2 HSPD1 353/4885HSPE1 192/4885DUSP26 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.